It has previously been shown that bromocriptine, a DRD2 receptor agonist, has positive effects on glucose tolerance, insulin sensitivity, and cardiovascular risk in subjects with and without T2D [6, 42, 43] and is approved as a treatment for T2D in the USA by the FDA [44]. The gene discussed is INS; the disease is type 2 diabetes mellitus.